CBP-501
CBP-501, a cell-permeable calmodulin-binding peptide and a G2-abrogating drug candidate, inhibits the activity of multiple Ser216-specific kinases, such as MAPKAP-K2, C-Tak1, CHK1 and CHK2, with IC50 values of 0.9 μM, 1.4 μM 3.4 μM and 6.5 μM, respectively. CBP-501 is used for various types of cancer[1][2].
Product Specifications
CAS Number
565434-85-7
UNSPSC
12352209
Target
Calmodulin; Checkpoint Kinase (Chk) ; MAP3K; MAPKAPK2 (MK2)
Type
Peptides
Related Pathways
Cell Cycle/DNA Damage; MAPK/ERK Pathway; Membrane Transporter/Ion Channel
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cbp-501.html
Purity
99.75
Smiles
N=C(N)NCCC[C@H](C(O)=O)NC([C@@H](CCCNC(N)=N)NC([C@@H](CCC(N)=O)NC([C@@H](CCCNC(N)=N)NC([C@@H](CCCNC(N)=N)NC([C@@H](CCCNC(N)=N)NC([C@@H](CC1CCCCC1)NC([C@@H](CC2=C(F)C(F)=C(F)C(F)=C2F)NC([C@@H](CO)NC([C@@H](CC3=CNC4=CC=CC=C34)NC([C@@H](CO)NC([C@@H](CC5=CC=C(C(C6=CC=CC=C6)=O)C=C5)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O
Molecular Formula
C86H122F5N29O17
Molecular Weight
1929.06
References & Citations
[1]Enzler T, et al. A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma. Eur J Cancer. 2024 Apr;201:113950.|[2]Shi-Ken Sha, et al. Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint. Mol Cancer Ther. 2007 Jan;6 (1) :147-53.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
Phase 2
Isoform
Chk1; Chk2; MAP3K7/TAK1
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
